Role of Methadone As Co-Opioid Analgesic in Cancer Patients
18 Years
N/A
Both
Pain
Trial Information
Role of Methadone As Co-Opioid Analgesic in Cancer Patients
The Study Drugs:
Methadone and morphine are both designed to block pain receptors (cells that are sensitive
to particular drugs) in your nerves and brain.
Study Groups and Study Drug Administration:
If you are found to be eligible to take part in this study, you will be randomly assigned
(as in toss of a coin) to 1 of 2 groups. Participants in Group 1 will stay on morphine only.
Participants in Group 2 will receive morphine plus methadone. You will have an equal chance
(50/50) of being placed in either of the 2 groups. You, the medical staff, and study
researchers will not know which group you have been assigned to. If necessary, your doctor
will be able to find out what group you are in the event of an emergency.
Participants in Group 1 will take 2 doses of "slow-release" morphine by mouth every 12
hours, every day for 15 days (plus or minus 3 days). You will also have access to
"immediate-release" morphine to be used, as needed, for pain. If you need more than 3 of
these immediate-release doses in a 24-hour period, you should call your study doctor.
Participants in Group 2 will take 1 dose of slow-release morphine and 1 dose of methadone by
mouth every 12 hours, every day for 15 days (plus or minus 3 days). You will also have
access to immediate-release morphine to be used, as needed, for pain. If you need more than
3 of these immediate-release doses in a 24-hour period, you should call your study doctor.
You will complete a questionnaire once daily about symptoms and pain you may be
experiencing. It will take about 5 minutes to complete each time.
You will be provided with a drug diary to write down when and how often you take pain
medication.
Study Visits:
On Days 8 and 15 (plus or minus 3 days) the following test and procedures will be performed:
- You will complete 3 questionnaires about any side effects you may be having. They will
take about 15-20 minutes to complete.
- You will have tests to see how sensitive your skin is.
On Day 15 only (plus or minus 3 days), you will have blood (about 1 teaspoon) drawn to
measure kidney function.
Length of Study:
You will be off-study after Day 15 (plus or minus 3 days). You will be taken off study
early if the disease gets worse or intolerable side effects occur.
This is an investigational study. Methadone and morphine are both FDA approved and
commercially available. Their use together is investigational. Up to 60 patients will take
part in this study. All will be enrolled at M. D. Anderson.
Inclusion Criteria:
1. Individual reporting average pain score for the last 24 hours that is at least a 4 on
a numerical scale from 0 to 10 (0= no pain, 10=the worst possible pain) with a
history of cancer (active or no evidence of disease).
2. Individual is receiving strong opioids (morphine, fentanyl, oxycodone, hydromorphone)
for 3 weeks prior to enrollment.
3. Individual requires at least 150 mg of daily morphine equivalent daily dose for
cancer pain. Using the formula MEDD = dose X MEDD Factor (App L) it would be follows:
morphine: a 24 hour total oral intake (sum of PRN and around the clock doses) of 150
mg or greater would qualify the patient, for fentanyl alone: a 24 hour total
transdermal intake of 75mcg/h or greater would qualify the patient, for oxycodone
alone: a 24 hour total oral intake of 100 mg or greater would qualify the patient,
and for hydromorphone alone: a 24 hour total oral intake of 30 mg/day or greater
would qualify the patient.
4. Individual has the ability to receive morphine or methadone orally.
5. Individual has no known allergy of history of severe toxicity to morphine or
methadone.
6. Individual has normal cognition defined as normal state of arousal and absence of
obvious clinical findings of confusion, memory or concentration deficit.
7. Individual has adequate renal function (creatinine less or equal to 2.0 MG/DL)
8. Individual has a Zubrod performance status of 3 or lower.
9. Individual is willing to sign written informed consent.
10. Individual is 18 years of age or older.
11. Individual on stable doses(on same dose for at least one week) of nonopioid
analgesics including NSAIDS, corticosteroids, gabapentin, pregabalin, or
antidepressants prescribed for the purposes of pain control.
Exclusion Criteria:
1. Individual is determined incapable of completing the evaluation forms.
2. Individual with clinically evident impaired cognition.
3. Patient with MEDD greater than 600.
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Patient Objective Response
Outcome Description:
Patient objective response (OR) defined as a dose escalation index <20.
Outcome Time Frame:
Day 15 (+/- 3 days)
Safety Issue:
No
Principal Investigator
Sriram Yennurajalingam, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
M.D. Anderson Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
2006-0641
NCT ID:
NCT00558870
Start Date:
November 2007
Completion Date:
Related Keywords:
- Pain
- Solid Tumors
- Morphine
- Methadone
- Co-Opioid Analgesic
- Pain
Name | Location |
|---|---|
| UT MD Anderson Cancer Center | Houston, Texas 77030 |
